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Abstract
Background: Black individuals are far more likely than white individuals to develop end stage renal disease (ESRD).
However, earlier stages of chronic kidney disease (CKD) have been reported to be less prevalent among blacks.
This disparity remains poorly understood. The objective of this study was to evaluate whether the lower prevalence
of CKD among blacks in early stages of CKD might be due in part to an inability of the MDRD equation to
accurately determine early stages of CKD in both the black and white population.
Methods: We conducted a retrospective cohort study of 97, 451 patients seen in primary care clinic in Veterans
Integrated Service Network 2 (VISN 2) over a 7 year period to determine the prevalence of CKD using both the
Modification of Diet in Renal Disease (MDRD) Study equation and the more recently developed CKD Epidemiology
Collaboration (CKD-EPI) equation. Demographic data, comorbid conditions, prescription of medications, and
laboratory data were recorded. Logistic regression and quantile regression models were used to compare the
prevalence of estimated glomerular filtration rate (eGFR) categories between black and white individuals.
Results: The overall prevalence of CKD was lower when the CKD-EPI equation was used. Prevalence of CKD in
whites was 53.2% by MDRD and 48.4% by CKD-EPI, versus 34.1% by MDRD and 34.5% by CKD-EPI in blacks. The
cumulative logistic regression and quantile regression showed that when eGFR was calculated by the EPI method,
blacks were as likely to present with an eGFR value less than 60 mL/min/1.73 m2 as whites. Using the CKD-EPI
equation, blacks were more likely than white individuals to have stage 3b, 4 and 5 CKD. Using the MDRD method,
the prevalence in blacks was only higher than in whites for stage 4 and 5 CKD. Similar results were obtained when
the analysis was confined to patients over 65 years of age.
Conclusions: The MDRD equation overestimates the prevalence of CKD among whites and underestimates the
prevalence of CKD in blacks compared to the CKD-EPI equation.
Background
The incidence and prevalence of both CKD and ESRD in
the United States continue to increase [1]. Age-adjusted
ESRD rates are much higher for black individuals than
white individuals (998 versus 273 per million) [2]. This
disparity persists even after controlling for hypertension,
diabetes, demographic characteristics, socioeconomic sta-
tus and access to health care [3,4]. However studies have
shown that the prevalence of early stages of CKD is lower
in the black population. The Reasons for Geographic and
Racial Differences in Stroke (REGARDS) study, a nation-
ally representative sample of individuals 45 years and older
revealed that estimated GFR < 60 ml/min/1.73 m2 was
present in 49.9% of white participants compared to 33.7%
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of blacks [3]. The National Health and Nutrition Examina-
tion Survey (NHANES) III showed similar results [5].
Thus the relationship of the racial prevalence of CKD to
ESRD is complex, and not dependent solely on the preva-
lence of CKD.
These previous studies used a single serum creatinine
measurement to determine the estimated GFR, the pre-
sence or absence of CKD, and its staging. The Kidney Dis-
ease Outcomes Quality Initiative (KDOQI) definition of
CKD requires the determination of at least 2 serum creati-
nine measurements 3 months apart to document the pre-
sence of CKD [6]. The above studies also employed the
MDRD equation for determining eGFR, which has been
shown to underestimate GFR at higher values [7-9]. The
CKD-EPI equation was developed as a more accurate
determination of the GFR [10] and has been found to cor-
relate better with long term risk of end-stage renal disease
and mortality in a middle aged population [11]. We deter-
mined the prevalence of different stages of CKD using
both the MDRD and CKD-EPI equations among the black
versus white Veteran population in Veterans Integrated
Service Network 2 (VISN 2), a large cohort consisting of
all Veteran patients in central and western New York, and
compared the use of two versus one serum creatinine in
these equations. The objective of this study was to deter-
mine whether the lower prevalence of CKD among blacks
in early stages of CKD might be due in part to an inability
of the MDRD equation to accurately determine early
stages of CKD in both the black and white population.
Methods
This study was approved by the Buffalo VA Institutional
Review Board. Data was obtained from the VISN 2 net-
work (180,503 patients). All patients who were seen in pri-
mary care clinic in VISN2 from 4/1/2001 till 4/2008 were
screened to estimate GFR by MDRD and CKD-EPI equa-
tion. We defined CKD as an eGFR < 60 ml/min/1.73 m2
using the first recorded serum creatinine during this time
period. Proteinuria was not considered in the definition.
Demographic data obtained included age, gender, race,
weight, height, body mass index (BMI), smoking history,
and marital status. Race was determined by patient self
report. The following co-morbid conditions were obtained
from the clinical problem list by International Classifica-
tion of Disease- 9th Revision (ICD-9 codes): myocardial
infarction (MI), coronary artery disease (CAD), congestive
heart failure (CHF), peripheral vascular disease (PVD),
chronic obstructive pulmonary disease (COPD), depres-
sion, cancer, diabetes, dyslipidemia, and hypertension
(Table 1). Laboratory values for low density lipoprotein
(LDL), triglyceride (TG) and high density lipoprotein
(HDL) were obtained within 6 months of initial serum
creatinine.
Definitions and equations
Age was re-calculated at each serum creatinine mea-
surement as the difference in years between the date of
serum creatinine measurement and the date of birth.
Patients were stratified based on GFR estimated by
MDRD and CKD-EPI formulae.
The re-expressed MDRD [8] formula used was: eGFR =
175 × (Scr)-1.154 × age-0.203 × 0.742 (if female) × 1.212 (if
black), where Scr is serum creatinine in mg/dl and age is
expressed in years.
The CKD-EPI [10] formula used was: eGFR = 141 × min
(Scr/k, 1)a × max(Scr/k, 1)-1.209 × 0.993Age × 1.018(if
female) × 1.159 (if black), where Scr is serum creatinine in
mg/dl, k is 0.7 for females and 0.9 for males, a is -0.329
for females and -0.411 for males, min indicates the mini-
mum of Scr/k or 1, and max indicates the maximum of
Scr/k or 1.
Prevalence was calculated as the ratio of patients with
CKD to the total number of patients with at least two
eGFR measurements in the duration of follow up.
Patients with only one measurement were excluded.
CKD was classified into stages based on the KDOQI
guidelines [6] and National Institute for Health and Clini-
cal Excellence (NICE) guidelines [12] as follows: stage 3a:
GFR 45-59 ml/min per 1.73 m2, stage 3b: GFR 30-44 ml/
min per 1.73 m2, stage 4: GFR 15-29 ml/min per 1.73 m2,
and stage 5: GFR < 15 ml/min per 1.73 m2.
The first recorded creatinine value was used as the
index creatinine. CKD stages were stratified based on











Male 93.32% 95.21% < .0001
Female 6.68% 4.79%
Age (years)
20-39 11.21% 6.58% < .0001
40-59 58.43% 35.26%
60-69 13.29% 20.82%
≥ 70 17.07% 37.33%
BMI
< 25 24.20% 19.13% < .0001
25-30 34.93% 38.28%
30-40 35.07% 37.08%
> 40 5.79% 5.51%
Per Capita Income ($)
< 20,000 47.34% 17.21% < .0001
20,000 - 25,000 26.48% 38.75%
25,000 - 30,000 11.75% 24.03%
> 30,000 11.62% 18.01%
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the index creatinine when only one value of creatinine
was used. The stratification into the stages based on the
2 values was done only if both the eGFRs were less than
60 ml/min/1.73 m2 (minimum time before 2nd measure-
ment was 3 months). If the subsequent eGFR was more
than 60 ml/min per 1.73 m2 the patient was not consid-
ered to have CKD.
Statistical Analysis
Descriptive statistics were produced for the overall
population and for the black and white groups sepa-
rately. The descriptive statistics included patient demo-
graphics (age, gender, marital status, per capita income
group), clinical variables (BMI, HDL-C, LDL-C, trigly-
cerides) and comorbid conditions: MI, CAD, CHF, PVD,
COPD, depression, cancer, diabetes, dyslipidemia, and
hypertension). Proportions of patients with the above
characteristics in different eGFR categories were com-
pared using c2 test. Logistic regression was used to
determine the effects of baseline characteristics on CKD
condition as well as on classification in a particular
eGFR category with ≥ 90 ml/min per 1.73 m2 as the
reference category. The two methods (EPI and MDRD)
of calculation of eGFR were compared using the Cron-
bach’s alpha measure.
Racial differences were explored in several other ways.
First we ran individual logistic regressions of each eGFR
category with the ≥ 60 mL/min/1.73 m2 category as the
reference level. We computed both unadjusted and
adjusted odds ratios for blacks. Next we ran the cumula-
tive logistic regressions comparing patients at a given level
of eGFR with patients above that level. Again we com-
puted both unadjusted and adjusted odds ratios for the
African-American group. The adjusted model included
age, gender, COPD, cerebrovascular event, depression,
cancer, diabetes, dyslipidemia, hypertension, BMI group,
presence of any vascular disease and proteinuria. As the
distribution of patients, especially blacks, was not normal,
and we were interested in the lower end of the distribution
of eGFR, quantile regression models were built to examine
the change in the race parameter over different percen-
tiles. These models adjusted for the same variables used in
the logistic regression models but also included a fourth-
order polynomial of age. As there were significant age dif-
ferences between whites and blacks, sensitivity analyses
were done for patients above age 65 years. All the analyses
were performed using SAS 9.2 (SAS Institute, Cary, NC).
Statistical significance was set a = 0.05.
Results
A total of 180,503 patients were screened from 4/1/01
to 4/1/08. The final sample size was 97,451 after exclud-
ing patients with only one serum creatinine measure-
ment and those with race or date of birth missing
(Figure 1). Demographics are shown in Table 1. The
majority of patients were white and male. 28% of black
patients were above 60 years of age compared to 58% of
whites. Per capita income was lower for blacks. Table 2
shows the percentage of patients with CKD (eGFR < 60
ml/min per 1.73 m2 by CKD-EPI) with various comor-
bidities. Looking at underlying cardiovascular disease,
CAD, CHF, PVD, and CVA were all more likely to be
present in white individuals with CKD. The prevalence
of any diagnosis of vascular disease was 28.3% in whites
and 15.3% in blacks. Even hypertension was more likely
to be found in white individuals (62.2 vs. 59.8%). Dia-
betes and proteinuria were more commonly present in
black individuals. Figure 2 shows the unadjusted preva-
lence of CKD in the study population when only 1
serum creatinine versus 2 serum creatinine measure-
ments are used in the MDRD or CKD-EPI equation to
define CKD. Overall the prevalence was reduced by
almost 40% when 2 serum creatinine measurements are
used compared to the single serum creatinine preva-
lence. We examined whether the likelihood of a patient
having 1 versus 2 or more serum creatinine measure-
ments performed differed by race and found no signifi-
cant difference (data not shown).
It has been suggested that one of the reasons a greater
percentage of black patients are found to have ESRD as
opposed to earlier stages of CKD is that blacks present to
a primary care physician later in the course of their disease
[13]. Figure 3 shows the mean eGFR at first serum creati-
nine determination by CKD-EPI equation by age of
patients who entered the VA VISN 2 system after 2003.
Although serum creatinine was higher among blacks,
there was no difference in age-dependent eGFR between
Figure 1 Study design.
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black and white patients with CKD at time of entry into
the system.
The logistic regression for CKD showed that there was
no difference between blacks and whites in terms of
CKD prevalence (defined as less than 60 mL/min/1.73
m2 as calculated by the CKD-EPI method) when
adjusted for age and other comorbidities. This held true
whether CKD was based on one or two measurements
(data not shown). The adjusted cumulative logistic
regressions showed that when eGFR was calculated by
the CKD-EPI method, there was no difference (AOR
1.057, 95% CIs 0.981-1.139) between blacks and whites
at a cutpoint of eGFR of 60 ml/min/1.73 m2, but that
using the MDRD equation, there was a significantly
lower risk (AOR 0.669, CIs 0.623 to 0.72) for blacks to
have CKD at this cutpoint (Table 3). On the other hand,
blacks were more than three times as likely as whites to
have CKD stage 5 (eGFR < 15 mL/min/1.73 m2) (AOR
3.171 by CKD-EPI and 3.062 by MDRD) by both
equations.
Table 2 Patients with CKD (eGFR < 60 ml/min by CKD-EPI) with various comorbidities
Overall (%) Black (%) White (%) P value
Total # of Patients with ≥ 2 Labs 8.38% 91.62%
MI 2.68% 1.15% 2.82% < 0.001
CAD 17.42% 8.24% 18.26% < 0.001
CHF 5.98% 4.29% 6.13% < 0.001
PVD 9.55% 5.50% 9.92% < 0.001
CVA 8.12% 6.49% 8.27% < 0.001
Any Vascular Disease 27.25% 15.25% 28.34% < 0.001
Depression 11.00% 14.09% 10.72% < 0.001
Hypertension 62.05% 59.77% 62.26% < 0.001
Dyslipidemia 59.44% 40.30% 61.19% < 0.001
DM 27.76% 28.93% 27.66% 0.0137
Proteinuria 22.86% 29.42% 22.26% < 0.001
HDL < 40 mg/dL 39.40% 29.31% 40.32% < 0.001
LDL > 100 mg/dL 61.36% 59.73% 61.51% 0.908
TG > 200 mg/dL 21.83% 13.39% 22.60% < 0.001
Figure 2 Unadjusted prevalence of CKD in the study population when only 1 serum creatinine versus 2 serum creatinine
measurements is used in the MDRD or CKD-EPI equation. The prevalence of CKD is reduced by 40% when using 2 serum creatinines.
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Quantile regression adjusted for comorbidities and
fourth order polynomial for age (Figure 4) showed that
blacks generally had a significantly higher eGFR than
whites by the CKD-EPI method except at the lower end
of the eGFR distribution (below the 11.5th percentile
which corresponds to an eGFR of 48 ml/min/1.73 m2
for the combined population) where there was no differ-
ence between blacks and whites. However, below the 5th
percentile, eGFR was significantly lower for black
patients corresponding eGFR of 38 ml/min/1.73 m2).
That is, blacks were likely to have lower eGFR using the
CKD-EPI method in stages 3b, 4, and 5 CKD. On the
other hand, in stage 3a or non-CKD conditions, whites
were as likely as blacks to have a lower eGFR.
While the results for eGFR using the MDRD method
(Figure 5) were similar to those for the CKD-EPI method,
blacks had a higher eGFR value than whites above the 6th
percentile (corresponding to an eGFR of 41 ml/min/1.73
m2); and lower eGFR value below 1.5th percentile (corre-
sponding to an eGFR of 27 ml/min/1.73 m2). Therefore,
in stage 3a or non-CKD conditions, whites were likely to
have a lower eGFR. In stage 3b, both blacks and whites
had a similar eGFR while blacks had a lower eGFR in
stages 4 and 5. Similar results were obtained when the
analysis was confined to patients above age 65.
To determine whether the CKD-EPI equation estimates
GFR more accurately among blacks than the MDRD
equation, we used Cronbach’s alpha measure to compare
these two methods of estimating GFR. Figure 6 shows
the concordance between MDRD and CKD-EPI equa-
tions in black and white individuals according to eGFR
categories. The concordance between MDRD and CKD-



















Mean eGFR at 1st Measurement by Age (based on EPI) who Entered the System after 2003
Black White
Figure 3 Mean eGFR at first measurement after entry into VA VISN 2 health care system by CKD-EPI equation by race of patients.
Table 3 Racial difference (Black vs. White) in eGFR
distribution and odds ratio in cumulative logistic model
eGFR Category CKD-EPI method MDRD method
Adjusted OR Adjusted OR
≤ 89 Vs. ≥ 90 0.629 (0.595 to 0.665) 0.404 (0.382 to 0.427)
≤ 59 Vs. ≥ 60 1.057 (0.981 to 1.139) 0.669 (0.623 to 0.72)
≤ 44 Vs. ≥ 45 1.238 (1.114 to 1.376) 1.061 (0.951 to 1.184)
≤ 29 Vs. ≥ 30 1.616 (1.378 to 1.895) 1.498 (1.267 to 1.771)
< 15 Vs. ≥ 15 3.171 (2.458 to 4.09) 3.062 (2.35 to 3.989)
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Figure 4 Quantile regression adjusted for comorbidities and age (fourth order polynomial) for CKD-EPI equation. The X axis displays
eGFRs by quantiles (0-0.2 being the lowest 20% and 0.8- 1.0 being the highest 20%). The Y axis shows the difference in eGFR in ml/min in
blacks compared to whites. For example, a black individual with an eGFR at the 40th percentile would have an eGFR approximately 3 ml/min
higher than a white individual by CKD-EPI method. Using the MDRD equation, a black at the 40th percentile, would have an eGFR approximately
6 ml/min higher than a white individual.
Figure 5 Quantile regression adjusted for comorbidities and age (fourth order polynomial) for MDRD equation. The X axis displays
eGFRs by quantiles (0-0.2 being the lowest 20% and 0.8- 1.0 being the highest 20%). The Y axis shows the difference in eGFR in ml/min in
blacks compared to whites. For example, a black individual with an eGFR at the 40th percentile would have an eGFR approximately 3 ml/min
higher than a white individual by CKD-EPI method. Using the MDRD equation, a black at the 40th percentile, would have an eGFR approximately
6 ml/min higher than a white individual.
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The excellent concordance between two equations in
estimating GFR does not mean that these equations mea-
sure eGFR more accurately in blacks, only shows that
they have a high degree of agreement in measurement.
Discussion
We studied the prevalence of different stages of CKD
among blacks and whites in > 180,000 patients who were
seen in primary care clinic at VISN2, using MDRD and
CKD-EPI equations. The cumulative logistic regression
adjusted for age and other comorbidities showed that
when eGFR was calculated by the CKD- EPI method,
blacks were as likely as whites to present with an eGFR
value less than 60 mL/min/1.73 m2. Using the CKD-EPI
equation, blacks were more likely than white individuals to
have stage 3b, 4 and 5 CKD. When eGFR was calculated
by the MDRD method, the results were similar for values
below 30 mL/min/1.73 m2. There was considerable differ-
ence between the two methods above this value. Similar
results were also shown when quantile regression was
used or analysis was confined to patients above age
65 years.
It is well established that the risk for ESRD is higher
in black than white individuals, yet earlier stages of
CKD have been found to be more prevalent in whites
[1-5,14,15]. Clase et. al. examined the NHANES III data-
base and found that the prevalence rate of CKD (eGFR
< 60 ml/min/1.73 m2 by the original MDRD equation
[16]) in non-diabetic black males, black females, white
males, and white females was 4.2%, 6.2%, 9.2%, and
17.8%, respectively [17]. Coresh et.al. evaluated the
NHANES III database including diabetic individuals and
found a prevalence of eGFR < 60 ml/min per 1.73 m2 in
3.4% of black participants and 5.0% in white participants
using a single measurement of serum creatinine in the
simplified MDRD study equation [5]. In REGARDS,
McClellan et. al. found that the prevalence of an eGFR
< 60 ml/min per 1.73 m2 was 33.7% in black patients
and 49.9% in white patients using a single serum creati-
nine [3]. They examined the prevalence at different dec-
iles of eGFR and using eGFR > 60 ml/min per 1.73
m2as the reference, found that the odds ratio for a low
eGFR in blacks compared to whites increased as kidney
function declined, with an odds ratio of .46 for eGFR 50
to 59 ml/min per 1.73 m2 to an odds ratio of 2.56 for
an eGFR of 10-20 ml/min per 1.73 m2. This relationship
held true even after adjusting for age, gender, diabetes,
hypertension, history of myocardial infarction or stroke,
smoking status, and region of the country.
This inconsistency in prevalence between blacks and
whites in early CKD versus ESRD remains unexplained.
Several factors which have been proposed to explain this
[3,4,14,18-29]. There may be more rapid progression of
CKD in blacks due to less effective treatment of modifi-
able risk factors affecting the progression of CKD [18-22]
or differences in genetic [23,24] and environmental [25]
factors. Black patients with CKD may have a lower death
rate and be more likely to reach ESRD. Newsome et al
found that in a large cohort of CKD patients who had
suffered a myocardial infarction, black patients had better
survival after 3 years [26]. However, NHANES III data
showed that black individuals with CKD under 65 years
Figure 6 Concordance between MDRD and CKD-EPI equations in black and white individuals according to eGFR categories. On the X
axis, in ml/min, categories 1-6 correspond to the following eGFRs (ml/min): 1 = > 90, 2 = 60-89, 3 = 45-59, 4 = 30-44, 5 = 15-29, and 6 = < 15.
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of age were more likely to die than white individuals, but
there was no difference seen in individuals over 65 years
of age [27]. Likewise, a study using the VA national data-
base showed a higher mortality for black patients versus
white patients at all levels of baseline GFR [14]. We did
not examine mortality in this study.
Blacks may have higher prevalence of ESRD relative to
CKD because they present to the health care system later
in the course of kidney disease [13], we found no differ-
ence in baseline CKD-EPI eGFRs at time of entry to the
VA system between black and white individuals (Figure 3).
There may be differences in quality of care given to blacks
compared to whites. A study showed decreased use of car-
diovascular procedures in minorities which may affect
morbidity and mortality from cardiovascular events [28].
However, a study of treatment regimens for CKD in the
Department of Defense found similar compliance of care
for stage 3 and 4 CKD in black and white individuals [29].
Another explanation for lower prevalence of CKD
among the black population could be the lack of accurate
tools to estimate GFR. The MDRD equation was derived
from a large study of patients with chronic renal disease
[16] which includes a correction factor of 20.5% for blacks
for the same creatinine level compared to whites. This
equation is widely used in clinical laboratories to estimate
GFR. However it has been shown that this equation tends
to underestimate GFR in healthy individuals [7,8]. The
CKD-EPI equation was derived more recently in an
attempt to rectify the fact that the MDRD equation under-
estimated measured GFR at higher values [10]. This equa-
tion was found to be more accurate than the MDRD
equation, especially at higher GFRs. The sample popula-
tions used to develop the CKD-EPI equation and the
MDRD equation had a limited number of elderly patients.
However, the CKD-EPI population included 32% blacks
compared to only 15% in the MDRD sample population.
So it may be possible that CKD-EPI is a better equation
for GFR estimation in blacks. Delanaye et. al. recently
found a prevalence of stage 3 CKD of 11.04% using the
MDRD equation versus 7.98% using the CKD-EPI equa-
tion in a screen of 1992 individuals [30]. Their study used
a single creatinine measurement to define CKD and there
were no black patients in their study population.
In the present study, when GFR was determined by
CKD-EPI compared to MDRD, we found that the preva-
lence of earlier stages of CKD was not different in blacks
compared to whites. Additional file 1 Table 4 shows why
there were significant differences in classification of stages
of CKD using the 2 formulas. The patients who were initi-
ally classified in different eGFR categories by CKD-EPI
method were reclassified again by applying MDRD equa-
tion. In the overall patient group, 44.4% of patients who
were classified into the > 90 ml/min per 1.73 m2 eGFR
group by CKD-EPI were re-classified by MDRD to the
lower eGFR category of 60-89 ml/min per 1.73 m2. The
overall difference in the prevalence of patients falling in to
the 60-89 ml/min per 1.73 m2 eGFR group increased by
about 3.4% by using CKD-EPI (5.7% - 2.3% = 3.4%). The
most noticeable finding was a large increase in the number
of black individuals found to have stage 3a CKD (17%
higher) when determined by CKD-EPIwho were classified
to a no-CKD category (eGFR of 60-89 ml/min per 1.73
m2) by MDRD method. The number of white patients
classified as stage 3a did not change. Similarly, 6% of the
whites who were initially classified into an eGFR of 60-89
ml/min per 1.73 m2 (No-CKD category) by CKD-EPI
method were reclassified to an eGFR category of 45-59
ml/min per 1.73 m2 (CKD stage 3a) by MDRD method.
These observations suggest that the lower prevalence of
CKD among black individuals is due to underestimation
of earlier stages of CKD in blacks and overestimation of
earlier stages of CKD among whites by MDRD method.
There are certain limitations to this study. First, we have
not directly measured GFR. Proteinuria was not included
in the evaluation, but this would be more critical to a
study of progression rather than classification of CKD.
Although the VHA is the largest integrated health care
system in United States and utilizes a uniform data collec-
tion system, this is a retrospective study and some patients
had to be excluded due to lack of information about gen-
der and race. The study was done on individuals in the
VA system, and therefore may not be applicable to the
general population.
Conclusions
This the first report of the racial prevalence of CKD in a
large VA cohort using 2 serum creatinine measurements
and employing the CKD-EPI equation to estimate GFR.
Using an adjusted regression model, we found no differ-
ence in the prevalence of earlier stages of CKD in black
individuals relative to white individuals. We found that
the previously described higher prevalence of early stage
CKD in whites may be accounted for by differences in
classification of stages of CKD by the MDRD equation
relative to the more recently derived CKD-EPI equation.
The finding that the prevalence of early CKD is similar
between the two races does not fully explain why ESRD
is more prevalent in blacks. Further studies will be
required to understand why this racial disparity persists.
Additional material
Additional file 1: Table 4: Reclassification of CKD-EPI group by
MDRD equation. Table 4 shows why there were significant differences
in classification of stages of CKD using the 2 formulas. The patients who
were initially classified in different eGFR categories by CKD-EPI method
were reclassified again by applying MDRD equation.
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